Apple Extends Lead in AliveCor Heart Rate Tech Legal Fight

Apple has scored another major victory against AliveCor in their long-running legal battle over heart rate technology. A federal appeals court this week sided with Apple, affirming a 2024 ruling that Apple's updates to the Apple Watch constituted lawful product improvements, not anticompetitive actions. For Apple Watch users, this means continued access to the latest heart health features without the threat of interference.

AliveCor's Claims Rejected Again

The Ninth Circuit Court of Appeals firmly rejected AliveCor's antitrust claims. The heart monitoring company had argued that Apple illegally monopolized the market for heart rate analysis apps on watchOS. Specifically, AliveCor took issue with Apple's decision to replace the Heart Rate during Physical Observation (HRPO) algorithm with its heart rate neural network (HRNN) algorithm in watchOS 5. AliveCor alleged that this change was deliberately designed to cripple its ECG KardiaBand, preventing it from identifying irregular heart rhythms and eliminating competition.

Apple countered that it had every right to make its own design choices and should not be dictated by a third party. The court agreed, asserting that mandating support for older heart rate tech would require the court to micromanage Apple's engineering processes. The court further noted that Apple provides developers access to the same Tachogram API data used by Apple's own Irregular Rhythm Notification feature. This is a crucial point, as it demonstrates that Apple isn't withholding essential resources from competitors.

Innovation vs. Antitrust: Where the Court Draws the Line

The appeals court also rejected AliveCor's argument that Apple had a duty to share proprietary data. The court emphasized that antitrust laws generally don't force companies to collaborate with rivals. Furthermore, imposing such a requirement would stifle innovation and place undue burden on the judicial system. This ruling confirms the invalidation of three AliveCor patents related to heart rate monitoring, effectively reversing a previous International Trade Commission ruling that threatened an Apple Watch import ban. I remember a similar case back in my Genius Bar days; companies need to innovate, not litigate their way to success.

This legal victory further solidifies Apple's position in the wearables market and its commitment to health-focused features. While AliveCor may continue to pursue legal avenues, this ruling sends a clear message: innovation, not litigation, is the path to success. This win will likely embolden Apple to continue pushing the boundaries of what's possible in wearable health technology, ultimately benefiting consumers with more advanced and reliable health monitoring tools. Now, let's see what new health features Apple unveils at the next WWDC.